<?xml version='1.0' encoding='utf-8'?>
<document id="28089685"><sentence text="Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model."><entity charOffset="65-74" id="DDI-PubMed.28089685.s1.e0" text="Valsartan" /><entity charOffset="76-82" id="DDI-PubMed.28089685.s1.e1" text="LCZ696" /><pair ddi="false" e1="DDI-PubMed.28089685.s1.e0" e2="DDI-PubMed.28089685.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28089685.s1.e0" e2="DDI-PubMed.28089685.s1.e1" /></sentence><sentence text="Sacubitril/valsartan (LCZ696) has been approved for the treatment of heart failure"><entity charOffset="0-10" id="DDI-PubMed.28089685.s2.e0" text="Sacubitril" /><entity charOffset="11-20" id="DDI-PubMed.28089685.s2.e1" text="valsartan" /><entity charOffset="22-28" id="DDI-PubMed.28089685.s2.e2" text="LCZ696" /><pair ddi="false" e1="DDI-PubMed.28089685.s2.e0" e2="DDI-PubMed.28089685.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28089685.s2.e0" e2="DDI-PubMed.28089685.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28089685.s2.e0" e2="DDI-PubMed.28089685.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28089685.s2.e1" e2="DDI-PubMed.28089685.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28089685.s2.e1" e2="DDI-PubMed.28089685.s2.e2" /></sentence><sentence text=" Sacubitril is an inÂ vitro inhibitor of organic anion-transporting polypeptides (OATPs)"><entity charOffset="1-11" id="DDI-PubMed.28089685.s3.e0" text="Sacubitril" /></sentence><sentence text=" In clinical studies, LCZ696 increased atorvastatin Cmax by 1"><entity charOffset="39-51" id="DDI-PubMed.28089685.s4.e0" text="atorvastatin" /></sentence><sentence text="7-fold and area under the plasma concentration-time curve by 1" /><sentence text="3-fold, but had little or no effect on simvastatin or simvastatin acid exposure"><entity charOffset="39-50" id="DDI-PubMed.28089685.s6.e0" text="simvastatin" /><entity charOffset="54-70" id="DDI-PubMed.28089685.s6.e1" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.28089685.s6.e0" e2="DDI-PubMed.28089685.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28089685.s6.e0" e2="DDI-PubMed.28089685.s6.e1" /></sentence><sentence text=" A physiologically based pharmacokinetics modeling approach was applied to explore the underlying mechanisms behind the statin-specific LCZ696 drug interaction observations" /><sentence text=" The model incorporated OATP-mediated clearance (CLint,T) for simvastatin and simvastatin acid to successfully describe the pharmacokinetic profiles of either analyte in the absence or presence of LCZ696"><entity charOffset="62-73" id="DDI-PubMed.28089685.s8.e0" text="simvastatin" /><entity charOffset="78-94" id="DDI-PubMed.28089685.s8.e1" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.28089685.s8.e0" e2="DDI-PubMed.28089685.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28089685.s8.e0" e2="DDI-PubMed.28089685.s8.e1" /></sentence><sentence text=" Moreover, the model successfully described the clinically observed drug effect with atorvastatin"><entity charOffset="85-97" id="DDI-PubMed.28089685.s9.e0" text="atorvastatin" /></sentence><sentence text=" The simulations clarified the critical parameters responsible for the observation of a low, yet clinically relevant, drug-drug interaction DDI between sacubitril and atorvastatin and the lack of effect with simvastatin acid"><entity charOffset="152-162" id="DDI-PubMed.28089685.s10.e0" text="sacubitril" /><entity charOffset="167-179" id="DDI-PubMed.28089685.s10.e1" text="atorvastatin" /><entity charOffset="208-224" id="DDI-PubMed.28089685.s10.e2" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.28089685.s10.e0" e2="DDI-PubMed.28089685.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28089685.s10.e0" e2="DDI-PubMed.28089685.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28089685.s10.e0" e2="DDI-PubMed.28089685.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28089685.s10.e1" e2="DDI-PubMed.28089685.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28089685.s10.e1" e2="DDI-PubMed.28089685.s10.e2" /></sentence><sentence text=" Atorvastatin is administered in its active form and rapidly achieves Cmax that coincide with the low Cmax of sacubitril"><entity charOffset="1-13" id="DDI-PubMed.28089685.s11.e0" text="Atorvastatin" /></sentence><sentence text=" In contrast, simvastatin requires a hydrolysis step to the acid form and therefore is not present at the site of interactions at sacubitril concentrations that are inhibitory"><entity charOffset="14-25" id="DDI-PubMed.28089685.s12.e0" text="simvastatin" /></sentence><sentence text=" Similar models were used to evaluate the drug-drug interaction risk for additional OATP-transported statins which predicted to maximally result in a 1" /><sentence text="5-fold exposure increase" /><sentence text="" /></document>